RxDoctor Payments Data

Saarik Gupta

Cardiovascular Disease · Santa Monica, CANPI 1790217164

Payments from drug & device makers

$25,080in general payments, 2019–2025

Across 260 payments — averaging $96.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$9K
  • Medtronic$7K
  • Biotronik Inc.$3K
  • Boston Scientific$2K
  • Biosense Webster, Inc.$1K
  • Philips North America LLC$618
  • plus $2K from 19 others

What the payments were for

  • Grants$2,50010%
  • Travel & lodging$7,60630%
  • Food & beverage$14,33257%
  • Education$6423%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,080 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban18$22,406
PradaxaDabigatran Etexilate Mesylate23$5,960
Flecainide Acetate17$453
Pantoprazole Sodium31$354
ClopidogrelClopidogrel Bisulfate16$298
CefuroximeCefuroxime Axetil15$148
Metoprolol Succinate12$126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimPradaxa$18$5,96023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →